» Articles » PMID: 36176912

Non-apoptotic Cell Death-based Cancer Therapy: Molecular Mechanism, Pharmacological Modulators, and Nanomedicine

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2022 Sep 30
PMID 36176912
Authors
Affiliations
Soon will be listed here.
Abstract

As an emerging cancer therapeutic target, non-apoptotic cell death such as ferroptosis, necroptosis and pyroptosis, etc., has revealed significant potential in cancer treatment for bypassing apoptosis to enhance the undermined therapeutic efficacy triggered by apoptosis resistance. A variety of anticancer drugs, synthesized compounds and natural products have been proven recently to induce non-apoptotic cell death and exhibit excellent anti-tumor effects. Moreover, the convergence of nanotechnology with functional materials and biomedicine science has provided tremendous opportunities to construct non-apoptotic cell death-based nanomedicine for innovative cancer therapy. Nanocarriers are not only employed in targeted delivery of non-apoptotic inducers, but also used as therapeutic components to induce non-apoptotic cell death to achieve efficient tumor treatment. This review first introduces the main characteristics, the mechanism and various pharmacological modulators of different non-apoptotic cell death forms, including ferroptosis, necroptosis, pyroptosis, autophagy, paraptosis, lysosomal-dependent cell death, and oncosis. Second, we comprehensively review the latest progresses of nanomedicine that induces various forms of non-apoptotic cell death and focus on the nanomedicine targeting different pathways and components. Furthermore, the combination therapies of non-apoptotic cell death with photothermal therapy, photodynamic therapy, immunotherapy and other modalities are summarized. Finally, the challenges and future perspectives in this regard are also discussed.

Citing Articles

Iron and siRNA co-encapsulated ferritin nanocages induce ferroptosis synergistically for cancer therapy.

Liu D, Wang Y, Sun Q, Mei D, Wang X, Su Y Acta Pharm Sin B. 2025; 15(1):526-541.

PMID: 40041902 PMC: 11873607. DOI: 10.1016/j.apsb.2024.10.006.


The molecular and metabolic landscape of ferroptosis in respiratory diseases: Pharmacological aspects.

Wu T, Ji M, Li T, Luo L J Pharm Anal. 2025; 15(1):101050.

PMID: 40034685 PMC: 11873008. DOI: 10.1016/j.jpha.2024.101050.


Engineering nanozyme immunomodulator with magnetic targeting effect for cascade-enzyodynamic and ultrasound-reinforced metallo-immunotherapy in prostate carcinoma.

Wang Y, Li H, Lin J, Li Y, Zhang K, Li H Nat Commun. 2025; 16(1):1876.

PMID: 39987131 PMC: 11846840. DOI: 10.1038/s41467-025-57190-1.


Ferroptosis in thyroid cancer: mechanisms, current status, and treatment.

Tian W, Su X, Hu C, Chen D, Li P Front Oncol. 2025; 15:1495617.

PMID: 39917169 PMC: 11798778. DOI: 10.3389/fonc.2025.1495617.


Targeting Non-Apoptotic Pathways with the Cell Permeable TAT-Conjugated NOTCH1 RAM Fragment for Leukemia and Lymphoma Cells.

Uchimura R, Nishimura S, Ozaki M, Kurogi M, Kawahara K, Makise M ACS Omega. 2024; 9(50):49925-49934.

PMID: 39713683 PMC: 11656380. DOI: 10.1021/acsomega.4c08955.


References
1.
Xu Y, Ma H, Fang Y, Zhang Z, Shao J, Hong M . Cisplatin-induced necroptosis in TNFα dependent and independent pathways. Cell Signal. 2017; 31:112-123. DOI: 10.1016/j.cellsig.2017.01.004. View

2.
Kaiser W, Upton J, Mocarski E . Viral modulation of programmed necrosis. Curr Opin Virol. 2013; 3(3):296-306. PMC: 3821070. DOI: 10.1016/j.coviro.2013.05.019. View

3.
Hu J, Dong Y, Ding L, Dong Y, Wu Z, Wang W . Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduct Target Ther. 2019; 4:28. PMC: 6799825. DOI: 10.1038/s41392-019-0062-9. View

4.
Wan H, Chen J, Zhu X, Liu L, Wang J, Zhu X . Titania-Coated Gold Nano-Bipyramids for Blocking Autophagy Flux and Sensitizing Cancer Cells to Proteasome Inhibitor-Induced Death. Adv Sci (Weinh). 2018; 5(3):1700585. PMC: 5867123. DOI: 10.1002/advs.201700585. View

5.
Ursini F, Maiorino M . Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020; 152:175-185. DOI: 10.1016/j.freeradbiomed.2020.02.027. View